
Marshall Fritz
Investment & Venture Associate, Bioengineering PhD, HardTech, Physical AI, & Frontier Innovation
Chapel Hill, North Carolina
Portola Valley, California
Summary
Marshall Fritz possesses a robust academic background in bioengineering and chemical engineering, culminating in a PhD from UNC Chapel Hill, where his research focused on B-cell engineering for novel treatments in infectious diseases, autoimmune diseases, and cancers. His work emphasizes biotechnology, immunology, and gene therapy, contributing to significant publications in the field. unc+3
With a keen interest in venture capital and life science startups, Marshall transitioned his expertise from scientific research to investment and advisory roles. He has held positions as an Investment Associate/Strategist at Ligo Partners Family Office, Investment Associate at Newlin Ventures, and a Venture Catalyst Fellow at KickStart Venture Services, demonstrating a strong aptitude for evaluating and supporting emerging technologies and businesses. unc+1
Driven by a personal experience with surrogacy, Marshall co-founded Surrogacy Matchmaker (also known as BabyBumps) with his wife, Victoria Fritz, MD, where he serves as a Chief Operating Officer and Board Advisor. This venture reflects his commitment to professional and personal missions, focusing on supporting intended parents through their surrogacy journeys. thesurrogacymatchmaker+1
Marshall is also an entrepreneur, evidenced by his role as the founder of DOG WTR, a company focused on pet health and hydration. This initiative showcases his ability to identify market needs and develop innovative solutions in the pharmaceutical sciences domain. dogwtr
Work
Education
Writing
Transduction Enhancer Combinations for Improving Targeted Lentiviral Transduction of B Cells in vivo
May 1, 2025Research paper establishing a method for in situ engineering of B cells using transduction enhancers, showing significant improvement in transduction and increased serum levels of recombinant antibodies.
Challenges and opportunities in gene editing of B cells
December 1, 2022A review discussing past and current approaches to B cell engineering, and its promising applications in immunology research and therapeutic gene editing.